Phosphodiesterase (PDE) 5 inhibitors reduce cyclic guanylate monophosphate breakdown,
promoting vascular relaxation in the corpora cavernosa and penile erection during sexual …

Erectile dysfunction (ED) has multifactor pathogenesis, with neurological, vascular,
endocrinological and psychogenic components described. However, about 50-85% of ED …

Introduction Due to the prevalence of erectile dysfunction and impotence among men in
recent years, several pharmacotherapies have been considered for such problems …

In 2000, the World Health Organization (WHO) has recognized erectile dysfunction (ED) as a
worldwide public health concern. Based on an international consensus meeting, the WHO …

Erectile dysfunction (ED) is a common sexual disorder with numerous etiologies involving
multiple organ systems that leads to significant distress and decreased quality of life for the …

All three PDE5 inhibitors are targeting the same site of action eg PDE5 and this is why a
quite similar efficacy and safety profile could be expected and was finally proven in many …

Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection
sufficient for satisfactory sexual performance. 1 According to data from the Massachusetts …

The causes of male erectile dysfunction (ED) are quite variable and are now commonly
divided into etiologies such as ischemia, smooth muscle damage, or altered blood flow …

Introduction: The inhibition of cyclic nucleotide PDE5 has been clinically validated as an
effective treatment for erectile dysfunction and pulmonary arterial hypertension. There are …

Erectile dysfunction (ED) is a prevalent form of male sexual dysfunction. Phosphodiesterase
type 5 (PDE5) inhibitor is the first-line treatment for ED. Numerous well-designed and …